Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. (a foreign private issuer) on February 5, 2019. The filing serves to distribute a press release dated February 5, 2019, regarding a new strategic collaboration.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report of a specific corporate event and does not contain financial statements or performance data.
Material Changes and Corporate Developments
The primary material event disclosed is the commencement of a collaboration with Washington University. This partnership is in preparation for the company's first U.S. clinical trial utilizing Cellect's ApoGraft technology for bone marrow transplantations.
Guidance, Outlook, and Risks
The filing incorporates by reference the "Forward Looking Statements" contained within the attached press release. No specific financial guidance, quantitative outlook, or detailed risk factors are enumerated in the text of the Form 6-K itself, other than the general incorporation of the press release's forward-looking language.
Investor Verification Checklist
- Verify the specific terms and scope of the collaboration agreement with Washington University.
- Confirm the timeline and regulatory status for the proposed first U.S. clinical trial for ApoGraft.
- Review the full text of the attached press release (Exhibit 99.1) for detailed forward-looking statements and associated risks.
- Check subsequent filings for any updates on the clinical trial initiation or financial impact of the collaboration.